All manuscripts
Publications TCR T Cells

T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity

Published Journal Cancers

Share
No image preview

Overview

This study evaluates PRAME-specific TCR-Ts co-expressing a chimeric PD1-41BB receptor. These cells showed enhanced cytotoxicity against PRAME+ tumors in vitro and in vivo. G-Rex® were used for the 10-day expansion phase of T-cells after transduction.

What this paper found

Medigene investigators isolated a high-affinity, HLA-A2-restricted T-cell receptor against the cancer/testis antigen PRAME (TCR-027-004) from non-tolerized repertoires of healthy donors and co-expressed it in CD8+ T-cells with a chimeric PD1-41BB receptor that joins the PD-1 extracellular region to the 4-1BB signaling domain. T-cells were transduced twice retrovirally, then expanded for 10 days in G-Rex® flasks with IL-7 and IL-15 at 5 ng/mL twice weekly. Adding PD1-41BB increased IFN-γ release against PD-L1-positive tumor lines and preserved killing of 3D spheroids re-challenged on days 3, 7, 10 and 13 over 16 days, without altering functional avidity or healthy-cell recognition. In MelA375_PD-L1 xenografts, one dose of 10 million TCR-positive cells left five of seven mice without measurable tumor.

Note: The in vivo result comes from immunodeficient xenograft mice that received no supplementary human cytokines, so the activity reflects the transferred T-cells alone; no patients were treated in this study.

Remarkably, TCR-Ts co-expressing PD1-41BB were able to mediate complete tumor rejection. — Nadja Sailer, Ina Fetzer, Melanie Salvermoser, Monika Braun, Doris Brechtefeld, Christian Krendl, Christiane Geiger, Kathrin Mutze, Elfriede Noessner, Dolores J. Schendel, Maja Bürdek, Susanne Wilde, Daniel Sommermeyer, Cancers

Study details

Authors
Nadja Sailer, Ina Fetzer, Melanie Salvermoser, Monika Braun, Doris Brechtefeld, Christian Krendl, Christiane Geiger, Kathrin Mutze, Elfriede Noessner, Dolores J. Schendel, Maja Bürdek, Susanne Wilde, Daniel Sommermeyer
Institution
Medigene Immunotherapies GmbH, Planegg, Germany · Immunoanalytics-Research Group Tissue Control of Immunocytes (TCI), Helmholtz Zentrum München, Munich, Germany · Medigene AG, Planegg, Germany
Journal
Cancers
Year
2022
PMID / PMC
PMID: 35454906 · PMC
Cell type(s)
TCR T Cells
Application area
Solid tumor
Study phase
Preclinical

How G-Rex® was used

CD8+ T cells were transduced twice in Retronectin-coated 24-well plates (0.25–0.5 × 10^6 cells per well) and, 18 to 24 hours later, moved to G-Rex® flasks (Wilson Wolf) for a 10-day expansion. During that phase fresh IL-7 and IL-15 were added twice a week at 5 ng/mL each. The cells were then harvested from the G-Rex® flasks, checked for transduction rate and frozen.

Explore related

Full citation

Sailer N, Fetzer I, Salvermoser M, et al. T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity. Cancers (Basel). 2022;14(8):1998.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →